Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UnitedHealthcare Limits Immune Checkpoint Inhibitor Quantities — and Why You Can Appeal

Immune checkpoint inhibitors (ICIs) — including pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), and cemiplimab (Libtayo) — are among the most complex oncology benefits UHC administers. Quantity-limit denials typically occur when the plan's pharmacy or medical benefit system flags a dispense or infusion request as exceeding a pre-set frequency or cycle ceiling. These ceilings are administrative constructs — they do not override a prescriber's clinical judgment or the FDA-approved labeling for your specific indication.

## Why This Denial Is Appealable

The FDA-approved prescribing information for each of these agents specifies dosing schedules and continuation criteria that are indication-specific and, in some cases, patient-weight-adjusted. If your prescribed regimen is consistent with the approved label for your cancer type and line of therapy, the plan's administrative quantity limit does not constitute a clinically valid reason to deny access. Quantity-limit policies that conflict with FDA-approved use are routinely overturned on appeal when supported by prescriber documentation.

## Federal Appeal Framework

• Internal appeal (Level 1): You have the right under ACA §2719 and ERISA §503 to a full-and-fair internal review. Submit within the timeframe printed on your denial letter (commonly 180 days).
• External review: If the internal appeal is denied, you may escalate to an Independent Review Organization (IRO) under ACA §2719. The external-review window is generally within approximately four months of final internal denial — confirm the exact deadline on your denial notice.
• Expedited review: Because ICIs treat serious or life-threatening conditions, request expedited processing at every level. Expedited external review decisions are typically rendered within 72 hours.

## Concrete Appeal Steps and Timeline

1. Request the insurer's complete clinical coverage policy for your specific ICI and indication in writing. 2. Obtain the current FDA-approved prescribing label and identify the exact dosing schedule and continuation criteria for your tumor type and line of therapy. 3. Submit your internal appeal with a prescriber letter (see below) within the denial letter's stated deadline. 4. If denied internally, file for external IRO review before the four-month window closes.

## Documentation to Gather

• Diagnosis confirmation: Pathology report, biomarker/PD-L1/TMB testing results, and staging documentation confirming the indication covered by the prescribed ICI.
• Treatment history: Dates and outcomes of prior lines of therapy, establishing where this agent falls in your treatment sequence.
• Clinical severity: Oncology notes documenting ECOG/performance status, disease burden, and urgency of continued treatment.
• Prescriber medical-necessity letter: Your oncologist should state that the requested quantity and schedule are consistent with the FDA-approved label for your specific indication and that deviation would compromise treatment efficacy.

## Criteria-Mapping Structure

Create a two-column table. In the left column, copy each quantity-related requirement from (a) the insurer's published coverage policy and (b) the FDA-approved label for your indication. In the right column, cite the exact chart entry, lab value, or clinical note that satisfies each requirement. This side-by-side format forces the reviewer to address each element individually and is the most effective way to rebut an administrative quantity-limit denial.